Abiopharma

🔍 Myers Michael (Director)

Company: Quoin Pharmaceuticals, Ltd. (QNRX)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 20,490 shares of ADSs at $4.88 per share (Direct)
  Date: 2026-08-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 37,713.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 10,245 shares of Ordinary Warrants (Right to Buy) at $6.1 per share (Derivative)
  Date: 2026-08-31 | Code: P | Exercise: 2026-08-31 | equity_swap_involved: 0 | shares_owned_after: 10,245.00 | transaction_form_type: 4 | Footnotes: F2, F2, F3, F4, F1

Footnotes:

• F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
• F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
• F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
• F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.